Quintiles launches CRO in booming China drug market

In yet another sign of the eastward drift of clinical development work, Quintiles says it is setting up a new CRO in China to help developers with everything from clinical trial management to regulatory submissions. The move comes as Quintiles, which has a staff of 300 in the Asian country, is planning to double the number of workers it has there. "We have an aggressive growth plan for China," says Quintiles China GM Ling Zhen. Release